Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma

Protocol No
SWOG-S2308
Staff Member
Mehdi Hamadani
Phase
III
Summary

This study is being done to answer the following question:
Can the study drug mosunetuzumab work better than the usual treatment drug (rituximab) against low tumor burden follicular lymphoma?

Objective
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma?
We are doing this study to find out if this approach is better or worse than the usual approach to treating low tumor burden follicular lymphoma.
Status
OPEN TO ACCRUAL